$CVAC Meanwhile, in a call with reporters Thursday morning, a Food and Drug Administration official said that the agency’s external vaccine- advisory panel might meet on Oct. 22 to discuss a Covid-19 vaccine, according to Bloomberg. The official did not say which vaccine the panel would discuss, but Pfizer has said it hopes to have Phase 3 data on its vaccine by then.
The external advisory committee would likely need to weigh in before the FDA would issue an emergency-use authorization. And an Oct. 22 meeting would leave time for a vaccine to be approved before the election. Investors increasingly expect approval by then, despite worries from former FDA officials that the timing could undermine trust in the product.
All that comes after CureVac (CVAC) said early Thursday that it was in talks with the European Commission to sell it 225 million doses of its experimental Covid-19 vaccine, sending shares of the newly public stock up 14.7%.
News 
Market Data 
Discover 
